CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today announced that the Company's presentation time has moved to 8:40 a.m. local time (2:40 a.m. Eastern Daylight Time) on May 15, 2007 at the Acumen Biofin Rodman & Renshaw 4th Annual Global Healthcare Conference, which is being held May 14-15, 2007 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Daniel Passeri, Curis' President and CEO, will provide an overview of the status of Curis' business and collaborations. There will also be a corresponding webcast of the presentation, which can be accessed by visiting: http://www.wsw.com/webcast/rrshq11/cris
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit www.curis.com.
CONTACT: Curis, Inc. Michael P. Gray, 617-503-6632 CFO & COO email@example.com SOURCE: Curis, Inc.